Citation

Maguire L, Bullard T, Papa L. Am. J. Emerg. Med. 2021; 43: 54-58.

Copyright

(Copyright © 2021, Elsevier Publishing)

DOI

10.1016/j.ajem.2020.12.088

PMID

33524683

Abstract

INTRODUCTION: There are no emergent pharmaceutical interventions for acute suicidal ideation, a common presenting complaint in the ED. Ketamine is a NMDA agonist frequently used by ED physicians for sedation and analgesia. Prior evidence from studies conducted in inpatient psychiatry units suggests that ketamine may have a role in alleviating treatment-resistant depression as well as suicidal ideation.
METHODS: PubMed, MEDLINE, and Cochrane reviews were queried for articles related to keywords ketamine, suicidality, suicidal ideation, and emergency department/room. Relevant articles were selected and reviewed by two separate authors.
RESULTS: Three relevant, prospective studies were identified with a mean sample size of 25.7. Each was performed using 0.2 mg/kg ketamine for individuals receiving active treatment. Each study reported a decrease in depressive symptoms among those receiving ketamine. One study reported a significant reduction in SI when compared to placebo at 90 min that became non-significant by 230 min. No significant adverse events were reported in any study.
CONCLUSION: Current evidence suggests that ketamine is a promising, safe potential intervention for acute suicidality in the ED. Convincing evidence for efficacy of ketamine for acute suicidal ideation remains lacking, and this promising potential intervention should be further investigated.

Language: en

Keywords

Humans; Adult; Aged; Female; Male; Middle Aged; Adolescent; Young Adult; Treatment Outcome; Suicidal Ideation; Suicidal ideation; Emergency Service, Hospital; Emergency department; Ketamine; Psychiatric emergency; Depressive Disorder; Excitatory Amino Acid Antagonists; Acute suicidality